TY - JOUR
T1 - Chemical constituents of Trichosanthes kirilowii and their cytotoxic activities
AU - Minh, Chau Van
AU - Nhiem, Nguyen Xuan
AU - Yen, Hoang Thi
AU - Kiem, Phan Van
AU - Tai, Bui Huu
AU - Le Tuan Anh, Hoang
AU - Hien, Truong Thi Thu
AU - Park, Seon Ju
AU - Kim, Nanyoung
AU - Kim, Seung Hyun
N1 - Publisher Copyright:
© 2015 The Pharmaceutical Society of Korea.
PY - 2015/8/8
Y1 - 2015/8/8
N2 - Abstract One new lignan, trichobenzolignan (1), and seven known compounds, ligballinol (2), (-)-pinoresinol (3), ehletianol C (4), luteolin 7-O-β-D-glucopyranoside (5), chrysoeriol-7- O-β-D-glucopyranoside (6), 10α-cucurbita-5,24-dien-3β-ol (7), and arvenin I (8). Their structures were established on the basis of spectral and chemical evidence, which were in agreement with those reported in literature. The cytotoxic activities of these compounds were evaluated on four cancer cell lines such as A-549 (human lung cancer), HT-29 (human colon adenocarcinoma), OVCAR (human ovarian carcinoma), and MCF-7 (human breast cancer). As the results, compound 7 showed significant activity on HT-29 and OVCAR cancer cell lines with IC50 of 4.1 and 6.5 μM, respectively. Compounds 1, 5, 6, and 8 exhibited moderate activities in all cancer cell lines with IC50 ranging from 11.3 to 42.8 μM.
AB - Abstract One new lignan, trichobenzolignan (1), and seven known compounds, ligballinol (2), (-)-pinoresinol (3), ehletianol C (4), luteolin 7-O-β-D-glucopyranoside (5), chrysoeriol-7- O-β-D-glucopyranoside (6), 10α-cucurbita-5,24-dien-3β-ol (7), and arvenin I (8). Their structures were established on the basis of spectral and chemical evidence, which were in agreement with those reported in literature. The cytotoxic activities of these compounds were evaluated on four cancer cell lines such as A-549 (human lung cancer), HT-29 (human colon adenocarcinoma), OVCAR (human ovarian carcinoma), and MCF-7 (human breast cancer). As the results, compound 7 showed significant activity on HT-29 and OVCAR cancer cell lines with IC50 of 4.1 and 6.5 μM, respectively. Compounds 1, 5, 6, and 8 exhibited moderate activities in all cancer cell lines with IC50 ranging from 11.3 to 42.8 μM.
UR - http://www.scopus.com/inward/record.url?scp=84938748992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938748992&partnerID=8YFLogxK
U2 - 10.1007/s12272-014-0490-6
DO - 10.1007/s12272-014-0490-6
M3 - Article
C2 - 25630793
AN - SCOPUS:84938748992
SN - 0253-6269
VL - 38
SP - 1443
EP - 1448
JO - Archives of pharmacal research
JF - Archives of pharmacal research
IS - 8
M1 - 490
ER -
